Skip to content

Shenling Baizhu powder can inhibit inflammation and improve the progression of atopic dermatitis by claudin-1 /MyD88 signal

Shenling Baizhu powder can inhibit inflammation and improve the progression of atopic dermatitis by claudin-1 /MyD88 signal

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067459
Enrollment
Unknown
Registered
2023-01-09
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic dermatitis

Interventions

Test group:Shenling Baizhu powder

Sponsors

Affiliated Hospital of Hebei University of Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Patients who meet the above diagnostic criteria of traditional Chinese medicine and Western medicine; ? Age =3 years; Both gender and ethnicity; ? Stable vital signs; ? Patients with good compliance, who voluntarily accepted the treatment plan of the clinical experimental study and signed the informed consent.

Exclusion criteria

Exclusion criteria: ? Pregnant or lactating women, allergic to the ingredients in the drugs of the experimental group and the control group; ? patients with a history of mental illness; Accompanied by liver and kidney, tumor, digestive tract, cardiovascular and cerebrovascular diseases, blood diseases and other serious life-threatening serious primary diseases; ?Systemic use of antibiotics, hormones, immunosuppressants or traditional Chinese medicine in the past 1 month; ? Do not meet the inclusion criteria: not according to the prescribed regular medication, incomplete data or unable to judge the efficacy and other factors, affect the safety judgment or affect the efficacy judgment.

Design outcomes

Primary

MeasureTime frame
Percutaneous water loss;

Countries

China

Contacts

Public ContactGuoying

Affiliated Hospital of Hebei University of Technology

1065391627@qq.com15373474076

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026